Vimeo
LinkedIn
Instagram
Share |

FB People

With a family history that has seen fortunes rise and fall on numerous occasions, Maximillian Gehrmann discusses the main reasons why intergenerational wealth is lost.

With a family history that has seen fortunes rise and fall on numerous occasions, Maximillian Gehrmann discusses the main reasons why intergenerational wealth is lost.

With a family line that dates to the year 1000, Octavian Pilati learnt from an early age the weight and importance of legacy. But when a crisis saw him taking over the family business at the age of 26 and subsequently shepherding a successful exit, he saw an opportunity to break out on his own and advise others of the pitfalls of fractured family dynamics and unclear succession planning.

With a family line that dates to the year 1000, Octavian Pilati learnt from an early age the weight and importance of legacy. But when a crisis saw him taking over the family business at the age of 26 and subsequently shepherding a successful exit, he saw an opportunity to break out on his own and advise others of the pitfalls of fractured family dynamics and unclear succession planning.

The chairman of Campden Club’s two-day event on March 30 and 31 talks to Campden FB about his main takeaways.

The chairman of Campden Club’s two-day event on March 30 and 31 talks to Campden FB about his main takeaways.

As a well‐recognised premier international financial and wealth management centre with the second largest number of ultra-high-net-worth individuals in the world, Hong Kong offers many unique advantages for family offices to operate and grow, explains Christine Ho, deputy global head of FamilyOfficeHK at Invest Hong Kong.

As a well‐recognised premier international financial and wealth management centre with the second largest number of ultra-high-net-worth individuals in the world, Hong Kong offers many unique advantages for family offices to operate and grow, explains Christine Ho, deputy global head of FamilyOfficeHK at Invest Hong Kong.

Medtech company Edinburgh Biosciences (EBS) is working towards a global solution for the diagnosis and treatment of cataracts. Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum, chief executive officer Dr Graham Bell, explains the benefits and potential future applications of the technology.

Medtech company Edinburgh Biosciences (EBS) is working towards a global solution for the diagnosis and treatment of cataracts. Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum, chief executive officer Dr Graham Bell, explains the benefits and potential future applications of the technology.

Click here >>
Close